Lancy Co (002612) Fair Value & Analysis
Consumer Cyclical · CN · Market cap 5.3B CNY
Fair value as of: Jun 25, 2026
Analysis
Lancy Co (002612) currently trades at ¥11.89, while our model-based Fair Value estimate is ¥24.75 — implying the stock looks roughly 108.2% undervalued today. We read business quality at 84/100 (high quality), in the Consumer Cyclical sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
About the company
Lancy Co., Ltd., together with its subsidiaries, engages in the design, production, and sale of apparel and medical services in China and internationally. The company offers women's clothing under the LANCY, LIME, MoJo S.Phine, and m.tsubomi brands; and children's clothing under the Agabang, ETTOI, DearBaby, 2ya2yao, Putto, Design Skin, and other brands. It is also involved in the medical beauty business under the Milan Baiyu and HANJIN brands; provision of medical rejuvenation services under the Jingfu brand; and operation of medical cosmetology centers, including cosmetic surgery, dermatology, traditional Chinese medicine, micro plastic surgery, and cosmetic dentistry under the Gao Yisheng brand. The company exports its products. It sells its products through stores and online. The company was founded in 2000 and is based in Beijing, China.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Lancy Co (002612) undervalued?
What is the fair value of 002612?
What is the quality score of 002612?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.